Candel Therapeutics, Inc.
No enriched coverage for $CADL in the last 7 days.
Candel Therapeutics (CADL) stock surged over 190% in six months due to clinical progress. CAN-2409 showed 50% 24-month survival in NSCLC and 39% improvement in prostate cancer survival. CAN-3110 is in Phase 1b for glioblastoma. CADL partnered with EVERSANA and plans a BLA filing for CAN-2409 in Q4 2026.
NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.
Candel Therapeutics (Nasdaq: CADL) reported Q2 2026 results and updates. It plans a BLA for aglatimagene in localized intermediate- to high-risk prostate cancer in Q4 2026. Phase 3 data in The Lancet Oncology showed a 39% improvement in prostate cancer-specific DFS vs placebo after 58 months. Cash was $201.6M as of June 30, 2026.
Recent CADL coverage spans financial news, earnings and corporate actions.
In the last 30 days, CADL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($84K). The most active reporter was Tyagarajan Seshu, Chief Technology Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive Phase 3 data and regulatory filing plans could lift the stock sharply.
Despite higher loss, investors focus on upcoming BLA filing and trial progress.
Near-term trading focus is execution risk into the planned Q4 2026 BLA and the strength of the phase 3 efficacy readout (39% PCa-specific DFS improvement).
The filing adds concrete execution milestones toward a Q4 2026 BLA and expands the clinical pipeline, supporting a bullish risk-reward into regulatory review.
The filing is a routine inducement equity grant tied to a new CCO hire, with limited direct implications for near-term fundamentals.
alphai scores every news story that mentions CADL with an AI model for sentiment and relevance, and aggregates insider trades from Candel Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Candel Therapeutics (CADL) stock surged over 190% in six months due to clinical progress. CAN-2409 showed 50% 24-month survival in NSCLC and 39% improvement in prostate cancer survival. CAN-3110 is in Phase 1b for glioblastoma. CADL partnered with EVERSANA and plans a BLA filing for CAN-2409 in Q4 2026.
3 min readNeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.
4 min readCandel Therapeutics (Nasdaq: CADL) reported Q2 2026 results and updates. It plans a BLA for aglatimagene in localized intermediate- to high-risk prostate cancer in Q4 2026. Phase 3 data in The Lancet Oncology showed a 39% improvement in prostate cancer-specific DFS vs placebo after 58 months. Cash was $201.6M as of June 30, 2026.
7 min readCandel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights • Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 202
5 min readCandel Therapeutics (Nasdaq: CADL) said its Compensation Committee granted Mark Sims, Chief Commercial Officer, inducement stock options for 285,000 shares at a $10.03 exercise price on July 6, 2026. Options vest 25% after one year, then 75% in monthly installments, subject to continued service. Plan adopted Dec. 24, 2025.
2 min readCandel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001841387 false 0001841387 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23,
3 min readCandel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 cadl-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“ Agreement ”) is made between Candel Therapeutics, Inc., a Delaware corporation (the “ Company ”), and Charles Schoch. (the “ Executive ”) and is made effective as of June 12,
3 min readCandel Therapeutics, Inc. announced its strategy for advancing oncology programs, with CEO Paul Peter Tak presenting at the Stifel 2026 Virtual Targeted Oncology Forum. The company is focusing on its clinical pipeline, specifically in prostate cancer, non-small cell lung cancer (NSCLC), and recurrent glioma. This presentation offers an early look at Candel's strategy and research developments in the oncology sector, highlighting their commitment to patient-driven innovation and regulatory standards.
2 min readCandel Therapeutics, Inc. has released new extended follow-up data from its phase 3 trial for CAN-2409 in localized prostate cancer. The results, presented at the #AUA26 meeting, provide further insight into the efficacy and durability of the investigational immunotherapy. This comes alongside other recent company recognition, such as the CEO emphasizing patient engagement and the Chief Regulatory Officer being named among RAPSorg 50 for 50.
3 min readCandel Therapeutics (NASDAQ: CADL) reported positive extended follow-up results from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer. The immunotherapy, combined with standard radiotherapy, demonstrated a 39% improvement in prostate cancer-specific disease-free survival in the overall population and 41% in the intermediate-risk subgroup, with significant hazard ratios. The treatment was well-tolerated, and Candel plans to submit a Biologics License Application (BLA) in Q4 2026, positioning CAN-2409 as a potential new therapy in over 20 years.
3 min read
